- Research Article
1
- 10.1007/s13340-025-00829-7
Changes in eating behavior and diet-related quality of life in individuals treated with tirzepatide for type 2 diabetes.
- Jun 25, 2025
- Diabetology international
- Shiori Toga-Sato + 11 more +11
We investigated changes in eating behavior associated with the administration of tirzepatide and evaluated any changes in diet-related QOL due to tirzepatide. The study included 60 outpatients with type 2 diabetes mellitus who had been on tirzepatide for 3months. The changes in body weight and HbA1c levels of all participants were observed for 3months following the initiation of tirzepatide treatment. Simultaneously, we conducted a questionnaire survey that included questions on their eating behavior (Eating Behavior Questionnaire) and diet-related quality-of-Life (DDRQOL). HbA1c levels significantly reduced after the first month of administration from 7.40 ± 1.58% at the start to 6.78 ± 0.99% after 3months (p < 0.001). Body weight also significantly decreased from 80.7 ± 13.2kg at the start to 78.3 ± 12.9kg after 3months (p < 0.001). The total Eating Behavior Questionnaire score significantly reduced from 52.9 ± 10.9 points to 47.7 ± 9.9 points after 3months (p < 0.001). There was a strong positive correlation only between the variations of the total score of the Eating Behavior Questionnaire and weight variations (r = 0.363, p = 0.005). Regarding the scores by subscales of DDRQOL, "Satisfaction with diet" changed from 75.3 ± 14.5 points at the start to 73.9 ± 14.8 points after 3months, showing no significant changes (p = 0.335). "Burden of diet therapy" significantly increased from 50.8 ± 14.9 points to 56.1 ± 15.9 points (p = 0.002), as did "Perceived merits of diet therapy" from 57.9 ± 13.9 points to 61.8 ± 11.2 points (p = 0.035). Administration of tirzepatide improved eating behavior, leading to increased diet-related QOL and decreased HbA1c levels and body weight.
Read more